Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

Prior treatment

• Prior obesity treatment with surgery or a weight loss device.
• Current or history of (within 3 months prior to screening) treatment with medications that may cause significant weight gain.

Other illness

• Lifetime history of Type 1 or Type 2 diabetes
• Obesity caused by known endocrinologic disorders or by known congenital or acquired hypothalamic disease or monogenetic or syndromic forms of obesity.
• Family or personal history of MTC or MEN 2
• Presence or history of malignant neoplasms within the past 5 years prior to screening

• Adult male and female participants, aged ≥18 to ≤75
• BMI ≥23 kg/m2 at screening.
• Has been treated with incretin-based therapy for weight management at a stable dose for at least 3 continuous months prior to screening.
• Tolerating incretin-based therapy at the discretion of the investigator
• WL of at least 10% while on incretin-based therapy and with stable BW for at least 3 months prior to screening.
• Willing to maintain their current general diet and physical activity regimen throughout the study.